Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | ADIL | Common Stock | Purchase | $25.9K | +10K | +1.09% | $2.59 | 927K | Nov 29, 2021 | Direct | F1 |
transaction | ADIL | Common Stock | Purchase | $29.2K | +10.6K | +1.14% | $2.75 | 938K | Nov 30, 2021 | Direct | F2 |
Id | Content |
---|---|
F1 | The price reported in Column 4 is a weighted average price. These 10,000 shares of common stock were purchased in multiple transactions at prices ranging from $2.54 to $2.60, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 |
F2 | The price reported in Column 4 is a weighted average price. These 10,600 shares of common stock were purchased in multiple transactions at prices ranging from $2.5999 to $2.83, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4 |